Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Product Recall

FDA announces recall of Medtronic HVAD pump implant kits after 2 deaths, 19 serious injuries

This is a Class I recall, which means using the device can lead to serious injury or death.

March 2, 2021
Hypertension patients measured their blood pressure less frequently during the early months of the COVID-19 pandemic, according to new research published in Hypertension. In addition, when those patients did measure their blood pressure, the readings were less healthy than they had been before the pandemic.

How 64% of U.S. COVID-19 hospitalizations could have been avoided

“Medical providers should educate patients who may be at risk for severe COVID-19 and consider promoting preventive lifestyle measures,” one researcher said. 

February 25, 2021
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

FDA approves expanded indication for sacubitril/valsartan

Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF. 

February 17, 2021
Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid

Heart failure medication may offer relief for patients with COVID-related POTS

Overall, researchers found that ivabradine was a “safe and effective” POTS treatment associated with making significant improvements to patient heart rates and quality of life.

February 17, 2021
Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid

Ablation could be ‘a powerful new strategy’ for treating heart failure patients with atrial fibrillation

According to a new study published in Circulation, ablation was associated with numerous benefits over standard drug therapy.

February 12, 2021

Hospitalizations for heart failure on the rise

Heart failure patients are also more likely to be readmitted than they were in the recent past. 

February 11, 2021
coffee

Drinking coffee reduces the risk of heart failure—but not if it’s decaf

In fact, drinking decaffeinated coffee was associated with a significant increase in heart failure risk.

February 9, 2021

Sacubitril/valsartan improves self-reported quality of life for HFpEF patients

However, treatment with sacubitril/valsartan did not lead to improvements in hospitalizations for heart failure or all-cause mortality.

February 1, 2021
Displaying 329 - 336 of 907

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup